271 related articles for article (PubMed ID: 10726046)
21. Cerebral vascular accidents in young patients with essential thrombocythemia: relation with other known cardiovascular risk factors.
Randi ML; Fabris F; Cella G; Rossi C; Girolami A
Angiology; 1998 Jun; 49(6):477-81. PubMed ID: 9631894
[TBL] [Abstract][Full Text] [Related]
22. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
Wehmeier A; Daum I; Jamin H; Schneider W
Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
[TBL] [Abstract][Full Text] [Related]
23. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
24. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A
Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
[TBL] [Abstract][Full Text] [Related]
25. Essential thrombocythemia.
Brière JB
Orphanet J Rare Dis; 2007 Jan; 2():3. PubMed ID: 17210076
[TBL] [Abstract][Full Text] [Related]
26. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.
Michiels JJ; Berneman ZN; Schroyens W; Van Vliet HH
Platelets; 2004 Mar; 15(2):67-84. PubMed ID: 15154599
[TBL] [Abstract][Full Text] [Related]
27. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
[TBL] [Abstract][Full Text] [Related]
28. No treatment for low-risk thrombocythaemia: results from a prospective study.
Ruggeri M; Finazzi G; Tosetto A; Riva S; Rodeghiero F; Barbui T
Br J Haematol; 1998 Dec; 103(3):772-7. PubMed ID: 9858229
[TBL] [Abstract][Full Text] [Related]
29. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
Godfrey AL; Campbell PJ; MacLean C; Buck G; Cook J; Temple J; Wilkins BS; Wheatley K; Nangalia J; Grinfeld J; McMullin MF; Forsyth C; Kiladjian JJ; Green AR; Harrison CN; ; ; ;
J Clin Oncol; 2018 Dec; 36(34):3361-3369. PubMed ID: 30153096
[TBL] [Abstract][Full Text] [Related]
30. Sex and age as prognostic factors in essential thrombocythemia.
Randi ML; Fabris F; Rossi C; Tison T; Barbone E; Girolami A
Haematologica; 1992; 77(5):402-4. PubMed ID: 1483589
[TBL] [Abstract][Full Text] [Related]
31. Essential thrombocythemia and pregnancy.
Griesshammer M; Heimpel H; Pearson TC
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():57-63. PubMed ID: 8951773
[TBL] [Abstract][Full Text] [Related]
32. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of essential thrombocythemia].
Alvarez-Larrán A; Cervantes F; Besses C
Med Clin (Barc); 2013 Sep; 141(6):260-4. PubMed ID: 23490491
[TBL] [Abstract][Full Text] [Related]
34. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
[TBL] [Abstract][Full Text] [Related]
35. [Vascular complications of essential thrombocythemia].
Bellucci S
Bull Acad Natl Med; 2007 Mar; 191(3):519-30; discussion 530-3. PubMed ID: 18072651
[TBL] [Abstract][Full Text] [Related]
36. Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC; Gómez M
Eur J Haematol; 2015 Jan; 94(1):4-11. PubMed ID: 24814134
[TBL] [Abstract][Full Text] [Related]
37. Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.
Piccin A; Steurer M; Mitterer M; Blöchl EM; Marcheselli L; Pusceddu I; Marabese A; Bertozzi I; Corvetta D; Randi ML; Elli E; Pogliani EM; Veneri D; Perbellini O; Krampera M; Pacquola E; Gottardi M; Tiribelli M; Guella A; Innella B; Vivaldi P; De Biasi E; Sancetta R; Rocconi R; Bassan R; Gherlinzoni F; Pizzolo G; Gastl G; Cortelazzo S
Intern Emerg Med; 2015 Jun; 10(4):451-60. PubMed ID: 25585678
[TBL] [Abstract][Full Text] [Related]
38. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
[TBL] [Abstract][Full Text] [Related]
39. Clinical course of essential thrombocythemia in 147 cases.
Fenaux P; Simon M; Caulier MT; Lai JL; Goudemand J; Bauters F
Cancer; 1990 Aug; 66(3):549-56. PubMed ID: 2364366
[TBL] [Abstract][Full Text] [Related]
40. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
